中信里昂：升科伦博泰生物-B(06990)目标价至500.6港元 重申“跑赢大市”评级

Core Viewpoint - CITIC Securities has adjusted the valuation of Kelun-Botai Biopharmaceutical (06990) based on the latest data, raising the target price from HKD 328.4 to HKD 500.6, an increase of 52%, while maintaining an "Outperform" rating [1] Group 1 - The group's first mid-term product achieved sales of RMB 310 million, primarily driven by sac-TMT [1] - The expansion of indications for second-line non-small cell lung cancer (NSCLC) is expected to further support sales growth in the second half of 2025 [1]